SCHEMBL1882201

SCHEMBL1882201

CCN(CC)c1ccc(N(C(=O)CCl)C(C(=O)NC2CCCCC2)c2cccs2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
MAPT P10636 4/20 0.55
KDM4E B2RXH2 1/20 0.55
LMNA P02545 1/20 0.54
PRNP P04156 1/20 0.53
ALDH1A1 P00352 5/20 0.51
YAP1 P46937 1/20 0.51
TEAD4 Q15561 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
TDP1 Q9NUW8 1/20 0.50
USP2 O75604 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
THRB P10828 1/20 0.49
ALOX12 P18054 1/20 0.49
POLB P06746 2/20 0.47
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1887723 0.89 MAPT (0.54) SMN1; SMN2MEN1KMT2AMAPTKDM4E
SCHEMBL1888399 0.89 MAPT (0.62) SMN1; SMN2MEN1KMT2AMAPTKDM4E
SCHEMBL1887127 0.88 YAP1 (0.66) SMN1; SMN2MEN1KMT2AMAPTKDM4E
SCHEMBL1883383 0.87 MAPT (0.53) SMN1; SMN2MEN1KMT2AMAPTKDM4E
SCHEMBL12639416 0.87 SMN1; SMN2 (0.56) SMN1; SMN2MEN1KMT2AMAPTKDM4E
SCHEMBL1882881 0.86 SMN1; SMN2 (0.53) SMN1; SMN2MEN1KMT2AMAPTKDM4E
SCHEMBL21966273 0.82 GPX4 (0.67) SMN1; SMN2MEN1KMT2AMAPTKDM4E
SCHEMBL12639677 0.82 MAPT (0.53) SMN1; SMN2MEN1KMT2AMAPTKDM4E
SCHEMBL1889992 0.82 ALDH1A1 (0.65) SMN1; SMN2MEN1KMT2AMAPTKDM4E
SCHEMBL1888843 0.82 SMN1; SMN2 (0.68) SMN1; SMN2MEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519188-B2 Compounds which can be used for the treatment of cancers Marc-Henry Pitty (FR) 2013-08-27 US disclosed
US-8519188-B2 Compounds which can be used for the treatment of cancers Marc-Henry Pitty (FR) 2013-08-27 US disclosed
US-8519188-B2 Compounds which can be used for the treatment of cancers Marc-Henry Pitty (FR) 2013-08-27 US disclosed
EP-2307017-B1 COMPOUNDS WHICH CAN BE USED FOR THE TREATMENT OF CANCERS PITTY MARC HENRY (FR) 2013-08-14 EP disclosed
US-20110104162-A1 Compounds which can be used for the Treatment of Cancers CYTOMICS SYSTEMS (FR) 2011-05-05 US disclosed
US-20110104162-A1 Compounds which can be used for the Treatment of Cancers CYTOMICS SYSTEMS (FR) 2011-05-05 US disclosed
US-20110104162-A1 Compounds which can be used for the Treatment of Cancers CYTOMICS SYSTEMS (FR) 2011-05-05 US disclosed
WO-2009150248-A1 COMPOUNDS WHICH CAN BE USED FOR THE TREATMENT OF CANCERS CYTOMICS SYSTEMS (FR) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110104162-A1 Compounds which can be used for the Treatment of Cancers VHL, CYP11B2, SLC10A1 SMN1; SMN2 2101/4885MEN1 70/4885KMT2A 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.